"This theory has been around for many years," said Barbara Brenner, executive director of Breast Cancer Action. "If this works, it is a very exciting development for a lot of people who are thinking about how we can control not only cancer, but the price of cancer drugs."
The finding is confirming what many people have thought for a long time, Brenner added. But she stressed that aspirin would not be "a cure-all, it's only reducing the risk of estrogen positive-breast cancer."
Like the other experts, Brenner doesn't advise women to start taking aspirin to prevent breast cancer. "There are risks with aspirin, and there are people for whom aspirin is not indicated," she said. "But they might want to talk to their doctors about this study and whether aspirin is appropriate for them."
For more information on breast cancer, visit the U.S. National Cancer Institute.
SOURCES: Gretchen Gierach Ph.D., cancer prevention fellow, U.S. National Cancer Institute, Rockville, Md.; Eric J. Jacobs, Ph.D., Strategic Director, Pharmacoepidemiology, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta; Barbara Brenner, executive director, Breast Cancer Action, San Francisco; April 30, 2008, Breast Cancer Research